Table 1.
Patient characteristics
| Group | All patients | 2.0 Gy/day | 2.1 Gy/day | 2.2 Gy/day | P |
|---|---|---|---|---|---|
| Total dose (Gy) | 72.6–74/74.8–78a | 74/78a | 73.5/77.7a | 72.6/74.8a | |
| No. of patients | 348 | 74 | 101 | 173 | |
| Age (years) | 54–83 | 54–80 | 56–80 | 56–83 | 0.01b |
| (median) | 70 | 68 | 70 | 70 | |
| Initial PSA (ng/ml) | 2.6–283 | 3.2–283 | 4.6–241 | 2.6–248 | 0.95b |
| (median) | 11.3 | 11.1 | 11.5 | 10.8 | |
| Risk Low/intermediate/high | 27/92/156 | 10/20/44 | 14/31/56 | 6/64/103 | 0.01c |
| T stage 1/2/3 | 81/114/80 | 24/30/20 | 27/43/31 | 40/81/52 | 0.64c |
| ADT | 240 (87%) | 51 (69%) | 91 (90%) | 171 (99%) | <0.01c |
| Use of anticoagulant | 49 (18%) | 15 (20%) | 15 (15%) | 29 (17%) | 0.63c |
| Coexistent DM | 47 (17%) | 16 (22%) | 11 (11%) | 27 (16%) | 0.15c |
| Follow-up (months) | 18–157 | 25–157 | 20–123 | 18–94 | |
| (median) | 82 | 124 | 98 | 69 |
PSA = prostate-specific antigen, ADT = androgen deprivation therapy, DM = diabetes mellitus. aFor low-risk/intermediate- or high-risk patients. bExamined by one-factor analysis of variance. cExamined by chi-squared test.